Key Drivers
- Profitability Decline
- Rising Leverage
- Adequate Liquidity
AIAI Summary
Harrow's credible ophthalmology portfolio is now secondary to proving that TYRVAYA/BYOOVIZ/IHEEZO can restore ~75% margins and positive cash flow before rising debt ($301M) and interest costs erode the thin equity cushion; investors should wait for sustained margin, EBITDA, and cash-flow recovery rather than buy solely on an oversold chart.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Decline
- •Rising Leverage
- •Adequate Liquidity
HROW's strong 2025 profitability and liquidity have deteriorated sharply in 2026, with negative cash flow, rising leverage, and weakened equity making the premium valuation high risk.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Support forming
- •Oversold momentum
HROW fell 21% over the last month, remains bearish below its 21-day average, and while oversold conditions may support a bounce near $33.00–$33.10, a recovery above $34.20–$34.50 is needed to improve momentum.
Selling accelerated after 2026-09-04
Sentiment & News
Key News Insights:
- •Iheezo Comfort Gains
- •Investor Outreach
- •Portfolio Validation
Harrow's Iheezo study showed over 50% less injection discomfort while upcoming investor conferences may boost visibility.
The updates are moderately positive for Harrow, supporting product differentiation and investor awareness
Similar Companies in Healthcare
Other companies in the same sector with AI ratings